Trial Profile
A phase 1 study of healthy subjects and patients with rheumatoid arthritis receiving single doses of SAN-300 or placebo to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SAN-300.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs SAN 300 (Primary) ; SAN 300 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Santarus
- 28 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 28 Oct 2013 Results were presented at the Annual Meeting of the American College of Rheumatology (ACR-2013)
- 05 Mar 2013 Status changed from active, no longer recruiting to completed, according to a Santarus media release.